CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 13:41:58 2024-06-28 EDT | ||
| 15.6 EUR | +0.97% |
|
| Current month | +17.38% | ||
| 1 month | +20.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 15.6 | +0.97% |
| 24-06-27 | 15.45 | +0.26% |
| 24-06-26 | 15.41 | +1.12% |
| 24-06-25 | 15.24 | -1.80% |
| 24-06-24 | 15.52 | +4.23% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 01:41 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GF9 |
| ISIN | DE000VU8GF99 |
| Date issued | 2023-06-13 |
| Strike | 311.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.45 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.51 € |
|---|---|
| Lowest since issue | 4.58 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
